KalVista Pharmaceuticals to Showcase New Clinical Data on EKTERLY® (Sebetralstat) at the 2026 Global Angioedema Leadership Conference
KalVista Pharmaceuticals has announced a significant scientific presence at the upcoming 2026 Global Angioedema Leadership Conference, highlighting its continued commitment to advancing treatment options for patients living with Hereditary Angioedema (HAE). The company revealed that five scientific abstracts—among them a notable late-breaking submission—have been accepted for presentation at the prestigious international meeting, which will take place from March 26 to 29, 2026, in Madrid.
This strong representation underscores KalVista’s growing leadership in the development of innovative therapies for HAE, particularly its investigational oral plasma kallikrein inhibitor, EKTERLY® (sebetralstat). The data to be presented span clinical efficacy, patient experience, and real-world treatment patterns, offering a comprehensive view of how emerging therapies may reshape disease management.
Spotlight on Late-Breaking Pediatric Data
The centerpiece of KalVista’s presentations is a late-breaking abstract focused on the use of oral sebetralstat in pediatric patients. Titled “On-demand Oral Sebetralstat for Hereditary Angioedema Attacks in Children Aged 2–11: Interim Analysis of KONFIDENT-KID,” the study provides an early look at how this novel therapy performs in a younger population.
The findings will be shared during a poster session on Friday, March 27, followed by an oral presentation on Saturday, March 28 at 11:50 a.m. CET—an indication of the importance and anticipated interest in the data. The KONFIDENT-KID study represents a critical step in expanding treatment access to children, a group that often faces limited therapeutic options and unique disease management challenges.
Hereditary angioedema is characterized by recurrent, unpredictable episodes of severe swelling affecting various parts of the body, including the abdomen, extremities, face, and airway. In pediatric patients, the burden can be particularly significant, impacting quality of life, school attendance, and overall well-being. An effective oral, on-demand therapy could represent a major advancement over current injectable treatments, which can be difficult to administer and may cause distress in younger patients.
Expanding Insights from the KONFIDENT Program
In addition to the pediatric study, KalVista will present multiple posters derived from its broader KONFIDENT clinical program, which evaluates sebetralstat across diverse patient populations and real-world scenarios.
One of the key presentations, “On-demand Treatment Patterns of Hereditary Angioedema Attacks with Sebetralstat in the KONFIDENT-S Study,” explores how patients are using the therapy in practice. This analysis provides valuable insights into treatment timing, frequency, and outcomes, helping clinicians better understand how oral therapies may integrate into routine care.
The KONFIDENT-S study is particularly important because it reflects real-world usage patterns rather than strictly controlled clinical trial conditions. Such data are increasingly valued by healthcare providers and regulators alike, as they offer a more nuanced picture of how therapies perform outside of idealized settings.
Addressing Barriers to Current Therapies
Beyond clinical efficacy, KalVista is also shedding light on the practical and emotional challenges faced by patients with HAE. Two additional poster presentations draw on findings from international patient surveys, focusing on barriers to treatment and psychological impacts.
The first survey-based study, “Barriers to Treatment of Hereditary Angioedema Attacks Among Patients Using Subcutaneous On-Demand Therapies,” examines the obstacles patients encounter when relying on injectable treatments. These barriers may include difficulty with administration, delays in treatment, limited access, and concerns about side effects.
Such findings highlight the unmet need for more convenient and accessible treatment options. Oral therapies like sebetralstat have the potential to address many of these issues by simplifying administration and enabling faster intervention during acute attacks.
Understanding the Emotional Burden of HAE
The second survey presentation, “Anxiety in Patients Using Injectable On-Demand Treatments for Hereditary Angioedema Attacks,” delves into the psychological dimension of living with HAE. Anxiety is a common yet often underrecognized aspect of the disease, driven by the unpredictability of attacks and the fear of severe outcomes, particularly those involving airway obstruction.
For patients dependent on injectable therapies, anxiety may be compounded by concerns about timely access to treatment or the ability to self-administer during an attack. By capturing patient-reported experiences from an international cohort, this study adds an important human perspective to the clinical data.
Together, these survey-based insights reinforce the broader value proposition of oral treatments—not only in terms of efficacy but also in improving patient confidence, independence, and quality of life.
A Comprehensive Scientific Presence
The breadth of KalVista’s accepted abstracts reflects a multifaceted research strategy that goes beyond drug development to encompass patient experience, healthcare delivery, and real-world outcomes. By addressing both clinical and psychosocial aspects of HAE, the company is positioning itself at the forefront of patient-centered innovation in rare disease treatment.
The Global Angioedema Leadership Conference serves as a key platform for researchers, clinicians, and industry leaders to share the latest advances in angioedema research and care. KalVista’s prominent participation signals both the maturity of its clinical program and the growing anticipation surrounding sebetralstat as a potential first-in-class oral, on-demand therapy.
Access to Presentation Materials
Following the conference, KalVista has indicated that links to all presentations will be made available through the Publications section of its corporate website. This will allow a broader audience—including clinicians, researchers, and patients—to access and review the findings presented in Madrid.
As the field of hereditary angioedema continues to evolve, the need for more patient-friendly treatment options remains a central focus. KalVista’s latest data presentations contribute to a growing body of evidence supporting the potential of oral therapies to transform the treatment landscape.
With ongoing clinical development and increasing real-world insights, sebetralstat may represent a meaningful step forward in addressing both the clinical and everyday challenges faced by individuals living with HAE. The upcoming conference in Madrid is expected to further clarify its role and bring the medical community closer to a new standard of care in this rare but serious condition.
Source Link:https://www.businesswire.com/
